"Buy The Weakness" - Oppenheimer Reiterates Alnylam (ALNY) at Outperform, Vutrisiran Delay is Minor, Continue to Expect Approval
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $205.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY), following company's announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
